Abstract

Glioblastoma (GBM) is a heterogeneous and lethal brain cancer. These tumors are followed using magnetic resonance imaging (MRI), which is unable to precisely identify tumor cell invasion, impairing effective surgery and radiation planning. We present a novel hybrid model, based on multiparametric intensities, which combines machine learning (ML) with a mechanistic model of tumor growth to provide spatially resolved tumor cell density predictions. The ML component is an imaging data-driven graph-based semi-supervised learning model and we use the Proliferation-Invasion (PI) mechanistic tumor growth model. We thus refer to the hybrid model as the ML-PI model. The hybrid model was trained using 82 image-localized biopsies from 18 primary GBM patients with pre-operative MRI using a leave-one-patient-out cross validation framework. A Relief algorithm was developed to quantify relative contributions from the data sources. The ML-PI model statistically significantly outperformed (p < 0.001) both individual models, ML and PI, achieving a mean absolute predicted error (MAPE) of 0.106 ± 0.125 versus 0.199 ± 0.186 (ML) and 0.227 ± 0.215 (PI), respectively. Associated Pearson correlation coefficients for ML-PI, ML, and PI were 0.838, 0.518, and 0.437, respectively. The Relief algorithm showed the PI model had the greatest contribution to the result, emphasizing the importance of the hybrid model in achieving the high accuracy.

Highlights

  • Gadolinium contrast-enhanced T1-weighted (T1Gd) magnetic resonance imaging (MRI) serves as the clinical standard for guiding surgical resection and radiation therapy in glioblastoma (GBM), an aggressive primary brain tumor

  • We present a hybrid method, consisting of machine learning and mechanistic model components, for predicting the tumor cell density based on multi-parametric MRI

  • To find a single machine learning (ML)-PI model that could be applied to any patient, we looked for a single set of tuning parameters that minimized the mean absolute predicted error (MAPE) across all patients

Read more

Summary

Introduction

Gadolinium contrast-enhanced T1-weighted (T1Gd) MRI serves as the clinical standard for guiding surgical resection and radiation therapy in glioblastoma (GBM), an aggressive primary brain tumor. While the contrast enhancement on a T1Gd MRI highlights the areas of a disrupted blood-brain-barrier and not the tumor cells directly[1], this physiological disturbance does generally correlate with regions of higher tumor cell density[2]. This rule-of-thumb correlation is not accurate enough to ensure that spatially targeted therapies, guided by the T1Gd, will provide optimal outcomes. We have made use of a unique data set consisting of multiple image-localized biopsies from 18 patients to enable spatially heterogeneous predictions of tumor cell density throughout an individual tumor

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call